drugset / Trial / NCT03746535
Cardiovascular Disease Risk in Women With Endometriosis
Phase 0
Recruiting
40 enrolled
Yale University
National Heart, Lung, and Blood Institute (NHLBI) · collab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
To test the hypothesis that estrogen suppression impairs endothelial dysfunction in endometriosis.
Timeline
- Start
- 2022-07-01
- Primary completion
- 2025-12-01
- Completion
- 2026-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Elagolix | Small molecule | 400 mg | Oral |